BrocklehurstJ. C.: Incontinence in the elderly: the majority can be cured. Modern Geriatrics, August 19 (1976).
2.
FrewenW. K.: Urgency incontinence. Review of 100 cases. J. Obst. Gynec. Brit. Commonw., 79; 77 (1972).
3.
HebjörnS.: Treatment of female incontinence with Emeoronium Bromide. Urol. Intern.33; 120–129 (1978).
4.
KagN. G.: Emepronium Bromide in the management of high-tly urinary frequency and urinary incontinence. Practitioner, 204; 705 (1970).
5.
BowmanW. C., RandM. T.: Textbook of Pharmacology, p. 10, 14–17, 2nd ed., Blackwell Scientific Publ., Oxford1980.
6.
ArduiniM., NatiliG.: Cystometric evaluation of the decontracturant action of the new synthetic antispasmodic drug (Flavoxate) in neurogenic bladders. Minerva urol., 21; 127 (1969).
7.
BradleyD. V., CazortR. J.: Relief of bladder spasm by flavoxate. A comparative study. J. Clin. Pharmacol., 10; 65 (1970).
8.
HerlostW. P.: Double blind comparison of flavoxate and propantheline as urologic antispasmodic. Amer. J. Clin. Res., 1; 65 (1970).
9.
SetnikerI., RavasM. T., Da ReP.: Pharmacological properties of piperidinoethyl-3-meth flavone-8-carboxylate hydrocloride, a smooth muscle relaxant. J. Pharmacol. Exp. Ther., 130; 356–363 (1960).
10.
ThompsonI., LauveteR.: Oxybutinine in bladder spasm, neurogenic bladder and enuresis. Urology, 3; 452–454 (1976).
11.
GiacobiniS., CrucianiE., FagioliA., CerulliC., TenagliaR., GallucciM., GueraniA.: Studio comparativo tra prifinio bromuro (Riabal) e cloruro di ossibutinina (Ditropan) nella terapia della instabilità vescicale. Urologia, 48; 535 (1981).
12.
ButazziP. J.: Oxybutinin chloride (Ditropan) in enuresis. J. Urol., 118; 46 (1977).
13.
LishF. M., LabuddeJ. A., PetersE. L., RobbinsI. S.: Oxybutinin. A muscolotropic antispasmodic drug with moderate anticholinergic action. Arch. intern. Pharmacodyn., 156; 467 (1965).
14.
FormanA., AnderssonK. E., HenrikssonL., RudT., UlmstenU.: Effects of Nifedipine on smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol. Toxicol., 43; 111–118 (1978).
15.
BodekerJ., SalimS. A., NagelA.: Wirkungen von Nifedipine bei urologischem Patient. Dtsch. med. Wsch., 101; 1866–1868 (1976).
16.
FleckensteinA.: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann. Rev. Pharmacol, Toxicol., 17; 149–166 (1977).
17.
ColeA. T., FriedF. A.: Favorable experiences with imipramine in the treatment of neurogenic bladder. J. Urol., 107; 44–45 (1972).
18.
McLeanR.E.G.: Imipramine hydrochloride (Tofranil) and enuresis. Amer. J. Psychiat., 117; 551 (1960).
19.
BowmanW. C., RandM. J.: Textbook of Pharmacology, p. 14–18, 2nd, Blackwell Scientific Publ., Oxford1980.
20.
Van RossumJ. M., Van den BrinkF. G.: Cumulative dose-response curves. Arch. Intern. Pharmacddyn., 143; 240–246 (1963).
BoltonT. B.: Mechanisms of action of trasmitters and other substances on smooth muscle. Physiol. Rev., 59; 606–718 (1979).
23.
PeiperU., GriebedL., WendeW.: Activation of vascular smooth muscle of rats aorta by noradrenaline and depolarization: two different mechanism. Pflugers Arch., 330; 74–89 (1971).
24.
FinneyD. J.: Statistical Methods in Biological Assay, 2nd ed., Ed. by Griffin, London1964.
25.
ArunklakshanzO., SchildM. O.: Some quantitative uses of drug antagonists. Brit. J. Pharmacol., 14; 48–58 (1959).
26.
BultitudeM. I., MillsN. M., ShuttleworthE. D.: Clinical and experimental studies on the section of prostaglandins and their synthesis inibitors on detrusor muscle in vitro and in vivo. Brit. J. Urol., 48; 631–637 (1976).
27.
JohnsA., PatonD. M.: Evidence for a role of prostaglandins in atropineresistant trasmission in the mammalian urinary bladder. Prostanglandins, 11; 595–597 (1976).
28.
ChooL. K., MitchelsonF.: The role of prostaglandins in the excitatory innervation of the rat urinary bladder. Prostaglandins, 13; 917–926 (1977).
29.
AndersonG. F., KohnK. I.: Intersections of calcium, prostaglandins and indomethacin on the smooth muscle of the blader. Pharmacology, 16; 306–313 (1978).
30.
PochG., HolzmannS.: Quantitative estimation of overadditive and underadditive drug effects: theoretical, additive dose-response curves. J. Pharmacol. Meth., 4; 179–188 (1980).